New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:59 EDTZGNX, ESRXZogenix price target lowered to $2.50 from $5 at Oppenheimer
Oppenheimer cut its price target on Zogenix (ZGNX) after coverage of the company's Zohydro painkiller was terminated by Express Scripts (ESRX). However, the firm thinks recent disappointing news about Zogenix is already reflected in the stock. Oppenheimer keeps an Outperform rating on the shares.
News For ZGNX;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:22 EDTESRXExpress Scripts CFO change a 'modest' concern, says Leerink
Subscribe for More Information
07:47 EDTESRXExpress Scripts new CFO experience reassuring, says Oppenheimer
Subscribe for More Information
December 15, 2014
16:40 EDTESRXExpress Scripts backs FY14 EPS view $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:39 EDTESRXExpress Scripts increases share repurchase authorization by 65M shares
Subscribe for More Information
16:37 EDTESRXExpress Scripts CFO Cathy Smith leaving company
Subscribe for More Information
07:40 EDTESRXExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 8, 2014
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use